CVD

US Department of Commerce Initiates AD/CVD Investigations & ASPA Witnesses Testify at ITC Preliminary Conference

Retrieved on: 
Thursday, November 16, 2023
Seafood, Commerce, ITC, CVD, Family, ASPA, Human

ASPA also submitted support forms for three non-ASPA processors, and AHSTAC filed its own support forms for nearly 50 boats and six processors.

Key Points: 
  • ASPA also submitted support forms for three non-ASPA processors, and AHSTAC filed its own support forms for nearly 50 boats and six processors.
  • Commerce will now determine whether imported shrimp from the subject countries is being dumped and/or illegally subsidized.
  • ASPA expects Commerce to issue preliminary findings and potential preliminary CVD margins by March 2024 and AD margins by May 2024.
  • We are thankful to Commerce for initiating the investigations and to the ITC for allowing us to present a case on behalf of the entire shrimp industry."

Global Graphene and 2D Materials Research Report 2024-2034: Emerging Applications in Quantum Dots and Fuel Cells

Retrieved on: 
Wednesday, November 15, 2023
Attention, Market, Research, Rhenium disulfide, Investment, Electronics, Quantum, Rhenium diselenide, Original equipment manufacturer, SWOT, Lubricant, Clothing, CVD, MXenes, Boron nitride, Filtration, Graphene, Carbon fibers, Rhenium

The Global Market for Graphene and 2D Materials 2024-2034 stands as the most comprehensive and current report on graphene and 2D materials available today.

Key Points: 
  • The Global Market for Graphene and 2D Materials 2024-2034 stands as the most comprehensive and current report on graphene and 2D materials available today.
  • Emerging applications of graphene, such as quantum dots, fuel cells, filtration, coatings, polymer composites, and lubricants, are examined in-depth.
  • The Global Market for Graphene and 2D Materials 2024-2034 contains:
    Assessment of graphene by market including applications, key benefits, market megatrends, market drivers for graphene, technology drawbacks, competing materials, potential consumption of graphene to 2034 and main players.
  • Assessment of graphene materials (CVD graphene, graphene nanoplatelets, graphene oxide, etc), intermediate products (graphene masterbatches, dispersions, etc) and final products with graphene embedded (e.g.

Pure Storage Drives Global Customer Breakthroughs with Enterprise-Scale AI Initiatives

Retrieved on: 
Monday, November 13, 2023
Machine learning, Health, Data management, LLM, NYSE, Information, Policy, Organization, Data science, CVD, Risk, Pure Storage, NCSOFT, Genomics, Cisco, Artificial intelligence, Automation, NVIDIA, Digital, DKFZ, PSTG, DGX, Pure, Cancer, TCO, Environment, AI, Ajay Singh, Certification, GE Technology Infrastructure, Dairy, Medical device

SANTA CLARA, Calif., Nov. 13, 2023 /PRNewswire/ -- Pure Storage® (NYSE: PSTG), the IT pioneer that delivers the world's most advanced data storage technology and services, today further strengthened its portfolio for artificial intelligence (AI) use cases and continued customer momentum across global AI deployments. Among the first enterprise data storage vendors to receive the NVIDIA DGX BasePOD certification, and now delivering with Cisco, new Cisco Validated Designs for FlashStack for AI, Pure Storage continues to provide enterprises with efficient, reliable access to data in support of new AI applications, underpinning modern, scalable business outcomes.

Key Points: 
  • With NVIDIA DGX BasePOD certification and expanded enterprise AI solutions, Pure Storage delivers simplified and efficient AI-ready storage infrastructure
    SANTA CLARA, Calif., Nov. 13, 2023 /PRNewswire/ -- Pure Storage® (NYSE: PSTG), the IT pioneer that delivers the world's most advanced data storage technology and services, today further strengthened its portfolio for artificial intelligence (AI) use cases and continued customer momentum across global AI deployments.
  • Powering the most advanced AI projects globally, Pure Storage empowers customers to launch AI initiatives at any scale, providing a flexible data storage foundation that grows as needs evolve.
  • Critical advancements to the Pure Storage portfolio include:
    AIRI®: Pure Storage has been at the forefront of optimized AI storage since the launch of FlashBlade® in 2017 and AIRI, its AI-Ready Infrastructure reference architecture co-developed with NVIDIA, in 2018.
  • Pure Storage offers the efficient, high performance storage platform required for AI that is automated, future-proof, and adaptable to evolving needs, catering to a broad spectrum of high-performance AI requirements.

AMGEN PRESENTS NEW CARDIOVASCULAR RESEARCH AT AHA 2023

Retrieved on: 
Friday, November 10, 2023
Massachusetts General Hospital, Moyamoya disease, Research, Safety, Lipoprotein(a), Deficit spending, Consortium, Risk, AHA, Cholesterol, Hospital, Cardiovascular disease, Patient, Small RNA, OLE, LDL, Function (mathematics), MACE, American Heart Association, Stroke, Harvard Medical School, RNA, CVD, Splenic infarction, ASCVD, Dementia, Cardiology, Cone Health Women's Hospital, AMGN, Pharmaceutical industry, Evolocumab, Brigham, OCEAN, Amgen

THOUSAND OAKS, Calif., Nov. 10, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data reinforcing the safety and efficacy of Repatha® (evolocumab) from the FOURIER Open Label Extension (OLE) [FOURIER-OLE] trial at the American Heart Association (AHA) Scientific Sessions 2023 in Philadelphia. These presentations will focus on the reduction of a known cardiovascular disease (CVD) risk factor, LDL "bad" cholesterol (LDL-C). Amgen will also present new research from the Phase 2 OCEAN(a)-DOSE study of its investigational small interfering RNA (siRNA) olpasiran that will focus on a primarily genetically determined and presumed independent CVD risk factor, lipoprotein(a) [Lp(a)].1,2,3,4,5

Key Points: 
  • These presentations will focus on the reduction of a known cardiovascular disease (CVD) risk factor, LDL "bad" cholesterol (LDL-C).
  • Amgen also shared new research from the OCEAN(a)-DOSE study on Lp(a) involving its investigational olpasiran.
  • Additional research presented at AHA will include Mass General Brigham Lp(a) registry data on whether the association between Lp(a) and major adverse cardiovascular events (MACE) differs based on baseline ASCVD status.
  • Amgen will reconvene the LDL-C Action Summit and the newly formed LDL Awareness to Action Implementation Consortium ahead of AHA.

AMRA Medical at AASLD The Liver Meeting® Showcases MRI-Based Technology and Muscle Biomarkers linked to liver disease severity and progression

Retrieved on: 
Thursday, November 9, 2023
Research, Surgery, Medical Devices, Clinical Trials, Health Technology, Biotechnology, Radiology, Health, Science, MELD, DSM-IV codes, Biomarker, Cirrhosis, Liver, Prevalence, Non-alcoholic fatty liver disease, Frailty, Liver disease, Phenotype, Multimedia, CVD, Circulatory system, Bilirubin, Mass, Type 2 diabetes, Cardiovascular disease, Abstract, AASLD, NAFLD, Patient, Sarcopenia, Medical imaging, Dietary supplement, T2D

A total of nine abstracts will be presented, focusing on how AMRA’s MRI-based muscle assessment score (MAsS) biomarkers are linked to liver disease severity and progression.

Key Points: 
  • A total of nine abstracts will be presented, focusing on how AMRA’s MRI-based muscle assessment score (MAsS) biomarkers are linked to liver disease severity and progression.
  • View the full release here: https://www.businesswire.com/news/home/20231109684555/en/
    The abstracts present MAsS as a promising tool to identify physical frailty and sarcopenia and as prognostic biomarkers for liver disease.
  • The AASLD’s The Liver Meeting® takes place November 10-14th in Boston, USA, with a number of AMRA attendees.
  • Those joining us at The Liver Meeting® can learn about how the MAsS biomarkers, muscle fat infiltration and muscle volume z-score, have been utilized in studies from early to end-stage liver disease.

CVD Equipment Corporation to Announce Third Quarter 2023 Financial Results on November 14, 2023

Retrieved on: 
Tuesday, November 7, 2023
Batteries, Maritime, Air, Transport, Hardware, Electronic Design Automation, Mobile, Wireless, Technology, Vehicle Technology, Science, Green Technology, Automotive, Mining, Minerals, Natural Resources, Other Science, Semiconductor, Other Manufacturing, EV, Electric Vehicles, Utilities, Research, Satellite, Oil, Gas, Contracts, General Automotive, Nanotechnology, Engineering, Alternative Energy, Chemicals, Plastics, Energy, Automotive Manufacturing, Aerospace, Defense, Manufacturing, Environment, Nanowire, Eastern Time Zone, CVV, Trinidad and Tobago Securities and Exchange Commission, CVD, Nature, Digital Equipment Corporation, Electronics, Silicon

CVD Equipment Corporation (NASDAQ: CVV ), a leading provider of chemical vapor deposition and thermal process equipment, announced today that it will release its third quarter 2023 financial results after the markets close on Tuesday, November 14, 2023.

Key Points: 
  • CVD Equipment Corporation (NASDAQ: CVV ), a leading provider of chemical vapor deposition and thermal process equipment, announced today that it will release its third quarter 2023 financial results after the markets close on Tuesday, November 14, 2023.
  • The Company will hold a conference call to discuss its results at 5:00 p.m. (Eastern Time) that day.
  • To participate in the live conference call, please dial toll free (877) 407-2991 or international (201) 389-0925.
  • Certain information in this press release contains statements that are forward-looking in nature and involve certain significant risks and uncertainties.

Cisco Showcases New Product Innovations Centered Around AI, Security and Observability at the 28th Annual Cisco Partner Summit

Retrieved on: 
Tuesday, November 7, 2023
Cloud, Partner, Nutanix, EVP, Pure Storage, Sustainability, AV Security Suite, AMD, Lake Pleasant View System Important Bird Area, Organization, CISCO, MLOps, Environment, Computer security, NVIDIA, University, Intel, Individual, Ecosystem, SAP, CVD, CSCO, Climate change, Red Hat, Telemetry, Investment, MIAMI, NetApp, Prize, Network equipment provider, Network, Cisco, Cisco Webex, AI

MIAMI BEACH, Fla., Nov. 7, 2023 /PRNewswire/ -- CISCO PARTNER SUMMIT -- Cisco (NASDAQ: CSCO) Partner Summit 2023 begins today, bringing together thousands of Cisco partners from around the world to network, learn and celebrate their shared successes with Cisco. Around 90 percent of Cisco's revenue flows through Cisco's partners, represented by tens of thousands of organizations from more than 150 countries.

Key Points: 
  • New Cisco Security Suites — User, Cloud, and Breach Protection Suites — offer a simplified, integrated, and economical way to buy and consume Cisco's security solutions.
  • Cisco launches observability ecosystem — enabling organizations to create new modules on the Cisco Observability Platform.
  • MIAMI BEACH, Fla., Nov. 7, 2023 /PRNewswire/ -- CISCO PARTNER SUMMIT -- Cisco (NASDAQ: CSCO) Partner Summit 2023 begins today, bringing together thousands of Cisco partners from around the world to network, learn and celebrate their shared successes with Cisco.
  • Cisco Partner Summit 2023 begins today, bringing together thousands of Cisco partners.

MSP Unveils Turbo II™ Vaporizers

Retrieved on: 
Monday, November 6, 2023
CVD, Science, TCO, MSP, ALD, Vapor pressure, Maintenance, Life, Propane

Shoreview, MN, Nov. 06, 2023 (GLOBE NEWSWIRE) -- MSP, a Division of TSI®, is thrilled to announce the launch of the new line of MSP Turbo II™ Vaporizers .

Key Points: 
  • Shoreview, MN, Nov. 06, 2023 (GLOBE NEWSWIRE) -- MSP, a Division of TSI®, is thrilled to announce the launch of the new line of MSP Turbo II™ Vaporizers .
  • Inspired by breakthroughs in the science of droplet atomization and evaporation, these innovative vaporizers are half the physical footprint of earlier versions, while delivering a staggering 200% increase in vapor output.
  • Elevate your CVD and ALD processes to unparalleled heights with the MSP Turbo II™ Vaporizers.
  • For further information or to request your Turbo II™ Vaporizer, visit tsi.com/MSP-Turbo-II/ or contact our sales team.

Verve and Lilly Relationship Expands to Include Verve’s In Vivo Gene Editing Programs Targeting PCSK9 and ANGPTL3

Retrieved on: 
Tuesday, October 31, 2023
Gene editing, Lilly, Eli Lilly and Company, Beam Therapeutics, Obesity, Moyamoya disease, Beam, Diabetes, CVD, Medicine, Risk, PCSK9, ANGPTL3, Therapy, Patient, ASCVD, Cardiovascular disease, Pharmaceutical industry, Verve

Lilly has acquired from Beam Therapeutics certain product rights to Verve’s cardiovascular in vivo gene editing programs targeting PCSK9 and ANGPTL3, as well as a third undisclosed cardiovascular disease (CVD) target.

Key Points: 
  • Lilly has acquired from Beam Therapeutics certain product rights to Verve’s cardiovascular in vivo gene editing programs targeting PCSK9 and ANGPTL3, as well as a third undisclosed cardiovascular disease (CVD) target.
  • Verve holds all product rights for the PCSK9 and ANGPTL3 programs outside the United States.
  • Verve is a leader in developing gene editing therapies for cardiovascular disease, and we are pleased to expand our relationship with Verve to develop much needed new treatment options for people with cardiovascular disease.”
    This transaction represents an expansion of the relationship between Verve and Lilly.
  • Previously, in June 2023 , Verve and Lilly had entered into an exclusive research collaboration focused on advancing Verve’s preclinical stage in vivo gene editing program targeting lipoprotein(a).

Integration of Multiple Biomarkers Fuels Robust 12.14% CAGR in Global Cardiac Biomarkers Market Through 2028 - ResearchAndMarkets.com

Retrieved on: 
Monday, November 6, 2023
Health, Cardiology, Viral Research and Diagnostic Laboratories, Heart failure, Health care, Biomarker, Acute coronary syndrome, Prevalence, Cardiovascular disease, Creatine kinase, Splenic infarction, Research, R, CVD, Growth, Hospital, Risk assessment, ACS, Troponin, Myoglobin, Diagnosis, Medical imaging, Medical device

The global cardiac biomarkers market is projected to experience robust growth, reaching $26.43 billion by 2028, with a compound annual growth rate (CAGR) of 12.14% from 2022 to 2028.

Key Points: 
  • The global cardiac biomarkers market is projected to experience robust growth, reaching $26.43 billion by 2028, with a compound annual growth rate (CAGR) of 12.14% from 2022 to 2028.
  • Key Market Trends & Drivers:
    Integration of Multiple Cardiac Biomarkers: Healthcare professionals are increasingly combining information from various cardiac biomarkers to gain a comprehensive understanding of a patient's cardiac health.
  • Increasing R&D Activities: The market is witnessing a surge in research and development (R&D) activities focused on novel cardiac biomarkers.
  • The global cardiac biomarkers market is highly competitive, with players ranging from pharmaceutical companies and diagnostic manufacturers to biotechnology firms and research institutions.